GPRC5B and acquired epidermolysis bullosa: To test the relevance of GPRC5B for neutrophil-mediated diseases in vivo, we employed the passive immunization model of bullous pemphigoid-like epidermolysis bullosa acquisita (EBA), a blistering skin disease in which deposition of autoantibodies to type VII collagen at dermal/epidermal junctions drives neutrophilic infiltration and consecutive skin inflammation33.